liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Imatinib reduces cholesterol uptake and matrix metalloproteinase activity in human THP-1 macrophages
Linköping University, Faculty of Medicine and Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Division of Cell Biology.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences. County Hospital Ryhov, Sweden.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences.
Show others and affiliations
2016 (English)In: Pharmacological Reports, ISSN 1734-1140, Vol. 68, no 1, 1-6 p.Article in journal (Refereed) PublishedText
Abstract [en]

Background: Imatinib mesylate (Glivec, formerly STI-571) is a selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. However, there are reports suggesting that imatinib could be atheroprotective by lowering plasma low-density lipoprotein (LDL). Aim: To investigate the potential inhibitory effect of imatinib on cholesterol uptake in human macrophages as well as its effect on matrix metalloproteinase (MMP) activity. Methods and results: Uptake of fluorescence-labeled LDL was analyzed using flow cytometry. Macrophages treated with imatinib showed a 23.5%, 27%, and 15% decrease in uptake of native LDL (p < 0.05), acetylated LDL (p < 0.01), and copper-modified oxidized LDL (p < 0.01), respectively. Gel based zymography showed that secretion and activity of MMP-2 and MMP-9 were inhibited by imatinib. Using GeneChip Whole Transcript Expression array analysis, no obvious gene candidates involved in the mechanisms of cholesterol metabolism or MMP regulation were found to be affected by imatinib. Instead, we found that imatinib up-regulated microRNA 155 (miR155) by 43.8% and down-regulated ADAM metallopeptidase domain 28 (ADAM28) by 41.4%. Both genes could potentially play an atheroprotective role and would be interesting targets in future studies. Conclusion: Our results indicate that imatinib causes post-translational inhibition with respect to cholesterol uptake and regulation of MMP-2 and MMP-9. More research is needed to further evaluate the role of imatinib in the regulation of other genes and processes. (c) 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.

Place, publisher, year, edition, pages
POLISH ACAD SCIENCES INST PHARMACOLOGY , 2016. Vol. 68, no 1, 1-6 p.
Keyword [en]
Atherosclerosis; Cholesterol; Imatinib; Macrophages
National Category
Biochemistry and Molecular Biology
Identifiers
URN: urn:nbn:se:liu:diva-125158DOI: 10.1016/j.pharep.2015.05.024ISI: 000368567800001PubMedID: 26721343OAI: oai:DiVA.org:liu-125158DiVA: diva2:903410
Note

Funding Agencies|Swedish Research Council [K2013-99X-22231-01-5]

Available from: 2016-02-15 Created: 2016-02-15 Last updated: 2016-03-14

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Gacic, JelenaVorkapic, EminaSlind Olsen, RenateSöderberg, DanielGustafsson, ThereseSkoglund, KarinWågsäter, Dick
By organisation
Faculty of Medicine and Health SciencesDivision of Cell BiologyDivision of Drug Research
In the same journal
Pharmacological Reports
Biochemistry and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 522 hits
ReferencesLink to record
Permanent link

Direct link